🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excellent presentation by my colleague Sarah P. Psutka MD MS UW Urology Fred Hutchinson Cancer Center on intermediate risk NMIBC trial designs & endpoints IBCG Debate/dialogue enables progress! Ashish M. Kamat, MD, MBBS Roger Li Shilpa Gupta Sia Daneshmand, M.D. Prof Param Mariappan 🇬🇧 🇲🇾 splernerMD Daniel Lin Claire de la Calle

Would have loved to join this season Sarah P. Psutka MD MS Shilpa Gupta but not joining IBCG retreat this year 👉 still a way to go to develop the best endpoints in IR #NMIBC that make clinical and regulatory sense and for from a #patient perspective Ashish M. Kamat, MD, MBBS Roger Li

Great catch up with #BladderCancer friends from Europe European Association of Urology (EAU) at the #IBCG24 in Houston. Joan Palou Redorta Marek Babjuk Paolo Gontero #MaurizioBrausi EAU guidelines IBCG

When friendship facilitates working together and improve patient care with #bladdercancer. #IBCG as a pushing and opening minds in order to progress in the diagnosis management!

Happy to share the link to the newly released summary of the NMIBC EAU guidelines! kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2… Thanks to European Association of Urology (EAU) EAU guidelines Maria J. Ribal for support and to Alex Masson-Lecomte Emma Jane Smith Prof Param Mariappan Shahrokh F. Shariat for the outstanding work!

Thank You for the inspiring and inclusive leadership, Ashish M. Kamat, MD, MBBS. Roger Li IBCG Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–... sciencedirect.com/science/articl…

Timely! Just out from #IBCG23 as we wrap up #IBCG24: Bladder-sparing Therapy for BCG–unresponsive NMIBC: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection authors.elsevier.com/a/1jfA914kplyy… IBCG World Bladder Cancer Patient Coalition Bladder Cancer Advocacy Network

#IBCG24 Retreat, the IBCG continues to lead the way in addressing global educational needs and learning gaps in order to improve care for people affected by #bladdercancer around the 🌎 All through proactive and dedicated global collaboration. A big thank you to

After the highly productive and collegiate #IBCG24, time for some of Team Europe to bid adios - returning to 🇩🇪 🇮🇹 🇳🇱 and 🇬🇧 Many thanks Ashish M. Kamat, MD, MBBS Shilpa Gupta Roger Li Patrick Hensley, MD and the whole IBCG team.

🌟 Flashback to #BladderCancerForum23! 🗣️ Watch Petros Grivas share invaluable insights from last year’s event. Ready for more? Don’t miss out on the 2024 Forum - secure your spot today! 👉ow.ly/joRp50T82C0

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Pleased to share the collaborative work between Sweden, Scotland and European Association of Urology (EAU) #NMIBC guidelines panel - a dataset of 9710 primary #NMIBC patients. This analysis describes the value in stratifying HG to HG/G2 and HG/G3. authors.elsevier.com/sd/article/S03…

Bowling for Bladder Cancer 🇺🇸 🇨🇦 🇬🇧 🇮🇹 🇳🇱 🇩🇪 🇦🇺 🇮🇳 🇲🇦 🇬🇷 🇨🇱 #IBCG24 IBCG #BladderCancer

Selamat menyambut Hari Merdeka! 🇲🇾 #MalaysiaIndependenceDay #SayaAnakMalaysia

Guidelines aim to harmonize and optimize urothelial carcinoma clinical trials. Ashish M. Kamat, MD, MBBS and Matt Galsky join Sam S. Chang MD, MBA to discuss new trial parameters and the urgent need for detailed guidelines due to the dynamic landscape of treatment > bit.ly/4bcYVxh

Thank you for everything, James. A statement from George Lucas and Lucasfilm: strw.rs/6002W5kU8

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 NEJM

Updated #SunRISe1 study results of 3 cohorts in BCG-unresp HR #NMIBC #ESMO24 C1: #TAR200🥨 + CET (n=53) C2: TAR-200 alone (n=85) C3: CET alone (n=28) ✅ CR at any time: C1 - 68%; C2 - 84%; C3 - 46% ✅ Estimated 12 months DOR rate in pts with TAR-200 monotherapy 65.7%

Exited to share the first results from the TOMBOLA trial presented at #ESMO24 by Jørgen Bjerggaard. We used tumor informed (WES; ddPCR) ctDNA analysis to guide Atezolizumab treatment after cystectomy using longitudinally collected blood samples. Key findings: •CtDNA-negative

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer is the 1st perioperative immune therapy study to show an OS in bladder cancer. Published in @nejm gbr01.safelinks.protection.outlook.com/?url=https%3A%…